GAMMA Investing’s Neurogene NGNE Stock Holding History

GAMMA Investing’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.1K	Buy	545 +10	+2%	+$275	﹤0.01%	2928
2026 Q1	$10.8K	Buy	535 +127	+31%	+$2.46K	﹤0.01%	3034
2025 Q4	$8.4K	Sell	408 -109	-21%	-$2.71K	﹤0.01%	3051
2025 Q3	$8.96K	Buy	517 +214	+71%	+$4.3K	﹤0.01%	2937
2025 Q2	$4.53K	Sell	303 -50	-14%	-$785	﹤0.01%	3164
2025 Q1	$4.13K	Buy	353 +219	+163%	+$3.8K	﹤0.01%	3157
2024 Q4	$3.06K	Buy	+134	New	+$4.99K	﹤0.01%	3085

Other funds holding NGNE

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing's NGNE Position: Q2 2026 in Review

GAMMA Investing increased its Neurogene (NGNE) stake by 1.9% in Q2 2026, buying an estimated $275 and bringing the position to 545 shares worth $17.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2928.

GAMMA Investing first reported a position in NGNE in Q4 2024 and has held it in 7 quarters since. 2 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

GAMMA Investing held 545 shares of Neurogene worth $17.1K as of Q2 2026.
GAMMA Investing bought 10 Neurogene shares in Q2 2026, an estimated $275.
Neurogene made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2928 holding.
GAMMA Investing first reported a position in Neurogene in Q4 2024 and has held it in 7 quarters since.
2 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.